Description
Using our intelligently designed and intuitive dataset, you can quickly understand how Cardiovascular Systems, Inc. (CSII) is lobbying the U.S. government, how much they’re spending on it, and most importantly – the bills and specific issues on which they lobby.
Gain an informational edge with our Lobbying Data Intelligence. Perform analysis by company, lobbyist, lobbying firm, government agency, or issue.
For lobbying firms: understand your competitors. Understand who is registering with who. Gain insight on quarterly reports and specific issues other firms are lobbying on.
Our lobbying data is collected and aggregated from the U.S. Senate Office of Public Records from 1999-present and is updated on a regular basis. We utilize advanced data science techniques to ensure accurate data points are collected and ingested, match similar entities across time, and tickerize publicly traded companies that lobby.
Our comprehensive and advanced lobbying database is completed with all the information you need, with more than 1.6 million lobbying contracts ready-for-analysis. We include detailed information on all aspects of federal lobbying, including the following fascinating attributes, among much more:
1. Clients: The publicly traded company, privately owned company, interest group, NGO, or state or local government that employs or retains a lobbyist or lobbying firm.
2. Registrants (Lobbying Firms): Either the name of the lobbying firm hired by the client, or the name of the client if the client employs in-house lobbyists.
3. Lobbyists: The names and past government work experience of the individual lobbyists working on a lobbying contract. 3. General Issues: The general issues for which clients lobby on (ex: ENV – Environment, TOB – Tobacco, FAM – Family Issues/Abortion).
4. Specific Issues: A long text description of the exact bills and specific issues for which clients lobby on.
5. Bills Lobbied On: The exact congressional bills and public/private laws lobbied on, parsed from lobbying report specific issues (ex: H.R. 2347, S. 1117, Tax Cuts and Jobs Act).
6. Agencies Lobbied: The names of one or more of 250+ government agencies lobbied on in the contract (ex: White House, FDA, DOD).
7. Foreign Entities: The names and origin countries of entities affiliated with the client (ex: BNP Paribas: France).
Gain access to our highly unique and actionable U.S. lobbying database. Further information on LobbyingData.com and our alternative datasets and database can be found on our website, or by contacting [email protected].
Frequently Asked Questions
What is Cardiovascular Systems, Inc. (CSII) lobbying for?
Summary:
– Lobbying firms: Liberty Partners Group, Llc
– General issues: Medicare/Medicaid, Health Issues
– Specific issues: Physician payment and policy issues relating to peripheral arterial disease and other cardiovascular issues; Amputation Reduction and Compassion Act, Supporting Medicare Providers Act of 2022., Consolidated Appropriations Act, Medicare Physician Fee Schedule; Medicare Physician Fee Schedule reform; H.R. 8800, 2023., Medicare Physician Fee Schedule; Medicare Physician Fee Schedule reform; S.610 – Protecting Medicare and American Farmers from Sequester Cuts Act; H.R.6048 – Medicare Stability for Patients and Providers Act., Medicare Physician Fee Schedule; Medicare Physician Fee Schedule reform., H.R. 2631., Physician payment and policy issues relating to peripheral arterial disease and other cardiovascular issues; S.610 – Protecting Medicare and American Farmers from Sequester Cuts Act; H.R.6048 – Medicare Stability for Patients and Providers Act; Amputation Reduction and Compassion Act., H.R. 2631; H.R. 8800, Supporting Medicare Providers Act of 2022; H.R.2617
– Government agencies: Senate, Department of Health & Human Services (HHS), Centers For Medicare and Medicaid Services (CMS), House of Representatives
One could infer that Cardiovascular Systems, Inc. is lobbying on these issues in order to influence healthcare policy and payment reform related to peripheral arterial disease and other cardiovascular issues. They may also be seeking to protect Medicare and Medicaid reimbursements for their products and services, which could be impacted by changes to the Medicare Physician Fee Schedule. The Amputation Reduction and Compassion Act may also be a priority for the company, given their focus on reducing amputations related to cardiovascular disease. Overall, the company is likely seeking to shape healthcare policy in a way that benefits their business interests and improves patient access to their products and services.
